{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:52:01Z","timestamp":1777503121885,"version":"3.51.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T00:00:00Z","timestamp":1558742400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s12185-019-02667-1","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T06:32:01Z","timestamp":1558765921000},"page":"213-227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Binimetinib, a novel MEK1\/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase\/Akt pathway"],"prefix":"10.1007","volume":"110","author":[{"given":"Kanae","family":"Sakakibara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Tsujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-ichiro","family":"Kida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nami","family":"Kurozumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Suemori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kitanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Arao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0812-9816","authenticated-orcid":false,"given":"Kaoru","family":"Tohyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,25]]},"reference":[{"key":"2667_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s12185-017-2303-4","volume":"106","author":"S Miyawaki","year":"2017","unstructured":"Miyawaki S. JSH guideline for tumors of hematopoietic and lymphoid tissues: leukemia 1. Acute myeloid leukemia (AML). Int J Hematol. 2017;106:310\u201325.","journal-title":"Int J Hematol."},{"key":"2667_CR2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s12185-017-2350-x","volume":"106","author":"J Takeuchi","year":"2017","unstructured":"Takeuchi J, Kusumoto S, Akiyama H, Kanda Y, Izutsu K. JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 3. Acute lymphoblastic leukemia\/lymphoblastic lymphoma (ALL\/LBL). Int J Hematol. 2017;106:732\u201347.","journal-title":"Int J Hematol."},{"key":"2667_CR3","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457\u201367.","journal-title":"Cancer Res"},{"key":"2667_CR4","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2013-09-381665","volume":"122","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013;122:4021\u201334.","journal-title":"Blood"},{"key":"2667_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012;150:264\u201378.","journal-title":"Cell"},{"key":"2667_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3324\/haematol.10869","volume":"92","author":"U Bacher","year":"2007","unstructured":"Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92:744\u201352.","journal-title":"Haematologica"},{"key":"2667_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","volume":"366","author":"JP Patel","year":"2012","unstructured":"Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079\u201389.","journal-title":"N Engl J Med"},{"key":"2667_CR8","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/sj.leu.2404009","volume":"19","author":"DH Christiansen","year":"2005","unstructured":"Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)\/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2005;19:2232\u201340.","journal-title":"Leukemia"},{"key":"2667_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ygyno.2014.01.008","volume":"133","author":"CR Miller","year":"2014","unstructured":"Miller CR, Oliver KE, Farley JH. MEK1\/2 inhibitors in the treatment of gynecologic malignancies. Gynecol Oncol. 2014;133:128\u201337.","journal-title":"Gynecol Oncol"},{"key":"2667_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1756-8722-6-27","volume":"6","author":"A Akinleye","year":"2013","unstructured":"Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6:27.","journal-title":"J Hematol Oncol."},{"key":"2667_CR11","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2015.04.028","volume":"364","author":"W Yao","year":"2015","unstructured":"Yao W, Yue P, Zhang G, Owonikoko TK, Khuri FR, Sun SY. Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K\/Akt signaling in human lung cancer cells. Cancer Lett. 2015;364:70\u20138.","journal-title":"Cancer Lett"},{"key":"2667_CR12","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/bjc.2014.475","volume":"111","author":"H Hamidi","year":"2014","unstructured":"Hamidi H, Lu M, Chau K, Anderson L, Fejzo M, Ginther C, et al. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition. Br J Cancer. 2014;111:1788\u2013801.","journal-title":"Br J Cancer"},{"key":"2667_CR13","doi-asserted-by":"crossref","first-page":"39595","DOI":"10.18632\/oncotarget.9153","volume":"7","author":"MS Lee","year":"2016","unstructured":"Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, et al. Efficacy of the combination of MEK and CDK4\/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 2016;7:39595\u2013608.","journal-title":"Oncotarget."},{"key":"2667_CR14","doi-asserted-by":"publisher","first-page":"e0147682","DOI":"10.1371\/journal.pone.0147682","volume":"11","author":"MK Kiessling","year":"2016","unstructured":"Kiessling MK, Curioni-Fontecedro A, Samaras P, Lang S, Scharl M, Aguzzi A, et al. Targeting the mTOR complex by everolimus in NRAS mutant neuroblastoma. PLoS One. 2016;11:e0147682.","journal-title":"PLoS One"},{"key":"2667_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1476-4598-13-45","volume":"13","author":"J Thumar","year":"2014","unstructured":"Thumar J, Shahbazian D, Aziz SA, Jilaveanu LB, Kluger HM. MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer. 2014;13:45.","journal-title":"Mol Cancer."},{"key":"2667_CR16","doi-asserted-by":"publisher","first-page":"14835","DOI":"10.18632\/oncotarget.11730","volume":"8","author":"M Kerstjens","year":"2017","unstructured":"Kerstjens M, Driessen EM, Willekes M, Pinhancos SS, Schneider P, Pieters R, et al. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations. Oncotarget. 2017;8:14835\u201346.","journal-title":"Oncotarget"},{"key":"2667_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/leu.2009.296","volume":"24","author":"A Matsuoka","year":"2010","unstructured":"Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010;24:748\u201355.","journal-title":"Leukemia"},{"key":"2667_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.exphem.2012.10.006","volume":"41","author":"T Tsujioka","year":"2013","unstructured":"Tsujioka T, Yokoi A, Uesugi M, Kishimoto M, Tochigi A, Suemori S, et al. Effects of DNA methyltransferase inhibitors (DNMTIs) on MDS-derived cell lines. Exp Hematol. 2013;41:189\u201397.","journal-title":"Exp Hematol"},{"key":"2667_CR19","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/s41375-018-0189-7","volume":"32","author":"JI Kida","year":"2018","unstructured":"Kida JI, Tsujioka T, Suemori SI, Okamoto S, Sakakibara K, Takahata T, et al. An MDS-derived cell line and a series of its sublines serve as an in vitro model for the leukemic evolution of MDS. Leukemia. 2018;32:1846\u201350.","journal-title":"Leukemia"},{"key":"2667_CR20","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1158\/1535-7163.MCT-06-0433","volume":"5","author":"ON Ikediobi","year":"2006","unstructured":"Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O\u2019Meara S, et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther. 2006;5:2606\u201312.","journal-title":"Mol Cancer Ther"},{"key":"2667_CR21","doi-asserted-by":"publisher","first-page":"e1054549","DOI":"10.1080\/23723556.2015.1054549","volume":"2","author":"Y Yu","year":"2015","unstructured":"Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, et al. The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2015;2:e1054549.","journal-title":"Mol Cell Oncol."},{"key":"2667_CR22","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1080\/10428190600565925","volume":"47","author":"F Ehmann","year":"2006","unstructured":"Ehmann F, Horn S, Garcia-Palma L, Wegner W, Fiedler W, Giehl K, et al. Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations. Leuk Lymphoma. 2006;47:1387\u201391.","journal-title":"Leuk Lymphoma"},{"key":"2667_CR23","unstructured":"Cancer Cell Line Encyclopedia. \n                    https:\/\/portals.broadinstitute.org\/ccle\n                    \n                  . Accessed 24 April 2019."},{"key":"2667_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0022-1759(92)90305-D","volume":"153","author":"MG Ormerod","year":"1992","unstructured":"Ormerod MG, Collins MK, Rodriguez-Tarduchy G, Robertson D. Apoptosis in interleukin-3-dependent haemopoietic cells. Quantification by two flow cytometric methods. J Immunol Methods. 1992;153:57\u201365.","journal-title":"J Immunol Methods."},{"key":"2667_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","volume":"184","author":"I Vermes","year":"1995","unstructured":"Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184:39\u201351.","journal-title":"J Immunol Methods."},{"key":"2667_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s12185-018-2527-y","volume":"108","author":"H Morita","year":"2018","unstructured":"Morita H, Matsuoka A, Kida JI, Tabata H, Tohyama K, Tohyama Y. KIF20A, highly expressed in immature hematopoietic cells, supports the growth of HL60 cell line. Int J Hematol. 2018;108:607\u201314.","journal-title":"Int J Hematol"},{"key":"2667_CR27","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1182\/blood-2005-09-3616","volume":"107","author":"Y Shi","year":"2006","unstructured":"Shi Y, Tohyama Y, Kadono T, He J, Miah SM, Hazama R, et al. Protein-tyrosine kinase Syk is required for pathogen engulfment in complement-mediated phagocytosis. Blood. 2006;107:4554\u201362.","journal-title":"Blood"},{"key":"2667_CR28","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA."},{"key":"2667_CR29","unstructured":"Gene set enrichment analysis: \n                    http:\/\/software.broadinstitute.org\/gsea\/index.jsp\n                    \n                  . Accessed 24 April 2019."},{"key":"2667_CR30","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/1535-7163.MCT-10-0037","volume":"9","author":"EB Garon","year":"2010","unstructured":"Garon EB, Finn RS, Hosmer W, Dering J, Ginther C, Adhami S, et al. Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther. 2010;9:1985\u201394.","journal-title":"Mol Cancer Ther"},{"key":"2667_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s00280-016-3019-5","volume":"77","author":"K Watanabe","year":"2016","unstructured":"Watanabe K, Otsu S, Hirashima Y, Morinaga R, Nishikawa K, Hisamatsu Y, et al. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016;77:1157\u201364.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2667_CR32","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2017.10","volume":"116","author":"JC Bendell","year":"2017","unstructured":"Bendell JC, Javle M, Bekaii-Saab TS, Finn RS, Wainberg ZA, Laheru DA, et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor. Br J Cancer. 2017;116:575\u201383.","journal-title":"Br J Cancer"},{"key":"2667_CR33","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1002\/ijc.24604","volume":"125","author":"K Balmanno","year":"2009","unstructured":"Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ. Intrinsic resistance to the MEK1\/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1\/2 signalling and\/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer. 2009;125:2332\u201341.","journal-title":"Int J Cancer"},{"key":"2667_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1158\/1535-7163.MCT-08-0972","volume":"8","author":"JJ Yeh","year":"2009","unstructured":"Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, et al. KRAS\/BRAF mutation status and ERK1\/2 activation as biomarkers for MEK1\/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther. 2009;8:834\u201343.","journal-title":"Mol Cancer Ther"},{"key":"2667_CR35","doi-asserted-by":"publisher","first-page":"8205","DOI":"10.1038\/sj.onc.1206878","volume":"22","author":"X Wan","year":"2003","unstructured":"Wan X, Helman LJ. Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells. Oncogene. 2003;22:8205\u201311.","journal-title":"Oncogene"},{"key":"2667_CR36","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1038\/leu.2017.157","volume":"31","author":"M Tesio","year":"2017","unstructured":"Tesio M, Trinquand A, Ballerini P, Hypolite G, Lhermitte L, Petit A, et al. Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia. Leukemia. 2017;31:2594\u2013600.","journal-title":"Leukemia"},{"key":"2667_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/cbr.2010.0802","volume":"27","author":"W He","year":"2012","unstructured":"He W, Wang X, Chen L, Guan X. A crosstalk imbalance between p27(Kip1) and its interacting molecules enhances breast carcinogenesis. Cancer Biother Radiopharm. 2012;27:399\u2013402.","journal-title":"Cancer Biother Radiopharm."},{"key":"2667_CR38","doi-asserted-by":"publisher","first-page":"14009","DOI":"10.1073\/pnas.0606316103","volume":"103","author":"I Timmerbeul","year":"2006","unstructured":"Timmerbeul I, Garrett-Engele CM, Kossatz U, Chen X, Firpo E, Grunwald V, et al. Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancer. Proc Natl Acad Sci USA. 2006;103:14009\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2667_CR39","doi-asserted-by":"publisher","first-page":"30301","DOI":"10.1074\/jbc.M411103200","volume":"280","author":"D Ungermannova","year":"2005","unstructured":"Ungermannova D, Gao Y, Liu X. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. J Biol Chem. 2005;280:30301\u20139.","journal-title":"J Biol Chem"},{"key":"2667_CR40","first-page":"1339","volume":"37","author":"G Chen","year":"2010","unstructured":"Chen G, Li G. Increased Cul1 expression promotes melanoma cell proliferation through regulating p27 expression. Int J Oncol. 2010;37:1339\u201344.","journal-title":"Int J Oncol"},{"key":"2667_CR41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.humpath.2010.09.003","volume":"42","author":"J Bai","year":"2011","unstructured":"Bai J, Zhou Y, Chen G, Zeng J, Ding J, Tan Y, et al. Overexpression of Cullin1 is associated with poor prognosis of patients with gastric cancer. Hum Pathol. 2011;42:375\u201383.","journal-title":"Hum Pathol"},{"key":"2667_CR42","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/jclinpath-2012-200847","volume":"65","author":"KW Min","year":"2012","unstructured":"Min KW, Kim DH, Do SI, Sohn JH, Chae SW, Pyo JS, et al. Diagnostic and prognostic relevance of Cullin1 expression in invasive ductal carcinoma of the breast. J Clin Pathol. 2012;65:896\u2013901.","journal-title":"J Clin Pathol"},{"key":"2667_CR43","doi-asserted-by":"publisher","first-page":"e91031","DOI":"10.1371\/journal.pone.0091031","volume":"9","author":"M Taskinen","year":"2014","unstructured":"Taskinen M, Louhimo R, Koivula S, Chen P, Rantanen V, Holte H, et al. Deregulation of COMMD1 is associated with poor prognosis in diffuse large B-cell lymphoma. PLoS One. 2014;9:e91031.","journal-title":"PLoS One"},{"key":"2667_CR44","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/leu.2016.258","volume":"31","author":"E Malek","year":"2017","unstructured":"Malek E, Abdel-Malek MA, Jagannathan S, Vad N, Karns R, Jegga AG, et al. Pharmacogenomics and chemical library screens reveal a novel SCF(SKP2) inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia. 2017;31:645\u201353.","journal-title":"Leukemia"},{"key":"2667_CR45","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/leu.2013.369","volume":"28","author":"A Lonetti","year":"2014","unstructured":"Lonetti A, Antunes IL, Chiarini F, Orsini E, Buontempo F, Ricci F, et al. Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia. 2014;28:1196\u2013206.","journal-title":"Leukemia"},{"key":"2667_CR46","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, et al. MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 2012;72:3228\u201337.","journal-title":"Cancer Res"},{"key":"2667_CR47","doi-asserted-by":"publisher","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-10-0902","volume":"70","author":"YN Gopal","year":"2010","unstructured":"Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010;70:8736\u201347.","journal-title":"Cancer Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-019-02667-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-019-02667-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T23:26:45Z","timestamp":1590276405000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-019-02667-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,25]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2667"],"URL":"https:\/\/doi.org\/10.1007\/s12185-019-02667-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,25]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}